Every Woman’s Essential for Self-Care in Breast, Digestive Tract, Bone, Heart and Kidney Health powered by Natural Vitamin K2 (MK-7)
Functions: Comprehensive formula for women's wellness including digestive tract health. Wholesome soy food helps prevent expression of breast cancer and improve mortality. Soy isoflavones and Vitamin K2 (MK-7, Menaquinone7) may exert combo effect in reducing arterial stiffness for better cardiovascular health and enhancing bone health and kidney function. The soy isoflavones may help in hormonal balance , thus may alleviate menopausal syndrome.
Benefits: Balance the feminine nutrition of women and strengthen their self-protection against breast cancer particularly by wholesome soy with optimized protein-carbohydrate ratio. Stable physiology, delicate and feminine at all times. Further protection on bone, blood vessel and heart health , and healthier kidney function by 180mcg natural vitamin K2 ( Natto Pharma MK-7 , Menaquinone7)
Key Active Ingredients: Premium Organic Soybean Powder, Non-GMO Soy Protein Powder, 90mg Fermented Chick Pea powder providing 180microgram natural Vitamin K2 in the form of MK-7 (Menaquinone-7) MenaQ7- NattoPharma, Norway), 200mg L-Citrulline Amino Acid, 50mg Mixed Palm Tocotrienols, 2 billion cfu Bifidobacterium longum BB536, Inulin (bifidogenic prebiotic) and Digestion Resistant Dextrin (water soluble dietary fibre)
Direction of Use: 1 - 2 sachets daily. Stir the product in about 100ml ( 1 sachet) -200ml (2 sachets) of warm water (<40 ° C) and drink immediately. Use a shaker to dissolve, more mouthfeel.
First Launch: 1 January 2002. New formula launch date: 1 November 2019
Scientifically formulated palatable premixed organic based soybean powder consumed as a beverage containing a blend of soybean powder and soy protein isolates powder rich in complete mix of 6 types of natural soy isoflavones (genistin/genistein, daidzin/daidzein and glycitin/glycitein) powered by optimum protein-carbohydrate ratio of 0.6 -1.0, dietary fibre and essential vitamins and minerals to help elevating quality of life of modern women in a highly stressful environment.
Each 20g powder contains approximately 30mg natural soy isoflavones . However, soy isoflavones content is very much depending on each soybean's natural constituent.
A healthy recommendation intake of soy isoflavones by American Institute for Cancer Research (AICR) latest continuous update report on breast cancer (2010) said the evidence is suggestive, soy reduces risk of breast cancer. Beyond breast cancer, AICR’s 2007 expert report concluded there was evidence linking soy or total isoflavone consumption to lower risk of cancers of the prostate and stomach. A handful of studies link soy or total isoflavone consumption with lower risk of lung and colon cancers.
Soy isoflavones may prevent postmenopausal osteoporosis and improve bone strength thus decreasing risk of fracture in menopausal women by increasing lumbar spine BMD and decreasing bone resorption marker urine deoxypyridinoline. A research team led by the University of Hull in the UK set out to determine whether soy and isoflavones could help protect women from osteoporosis. They gave 200 women who were within 2 years of the start of menopause either 30 grams (about an ounce) of Soy protein with 66 milligrams of isoflavone, or 30 grams of soy protein on its own, every day for 6 months. Women taking soy protein with isoflavones also had fewer signs of a risk of heart disease than those taking soy alone, the aims say. "While Thozhukat Sathyapalan, MD, who led the study.
Although soy food consumption among US women is substantially lower than among women in China (the average isoflavone intake among US women is 1-6 mg/day compared with 47 mg/day in our study population), soy food consumption in the United States has The percentage of persons eating soy products at least once per week was 28% in 2003, up from 15% in 1997.
MenaQ7® is the first and most clinically validated Vitamin K2 as MK-7 (menaquinone-7) available today for bone and cardiovascular health, and patented for cardiovascular health.
MK-7 is recognized in scientific literature for providing optimal activity and vitamin K status in the body, supporting bone and cardiovascular health, and MenaQ7® has demonstrated these strengths and benefits in human clinical trials with adult and child populations.
The Rotterdam Study (2004) shows that high dietary intake of Vitamin K2 - but not vitamin K1 - has a strong protective effect on cardiovascular health. Findings from this 10-year population-based study, which followed 4,807 initially healthy men and women > 55 years of age from start, indicate that eating foods rich in natural Vitamin K2 (at least 32 mcg/day) results in 50% reduction of arterial calcification, 50% reduction of cardiovascular risk, and 25% reduction of all-cause mortality.
This first intervention trial on MK-7 supplements and cardiovascular endpoints showed that 3-year supplementation with a daily, nutritional dose (180 mcg) of MenaQ7® was enough to actually decreased arterial stiffness in healthy post-menopausal women.
In 2013, Osteoporosis International published a groundbreaking double-blind, randomized, clinical trial that demonstrated for the first time clinically statistically significant protection of the vertebrae and the hip (femoral neck) against bone loss. This was attained with a nutritional dose of Vitamin K2 as MK-7 (MenaQ7® from NattoPharma) taken daily for three years.
In this study of 244 healthy post-menopausal women, the MenaQ7® group took 180 mcg daily and showed significantly decreased circulating uncarboxylated osteocalcin (ucOC), a well-established biomarker for bone and vitamin K status. After 3 years, both bone mineral content and bone mineral density, as well as bone strength were statistically significantly better for the MK-7 group compared to the placebo group.
Dialysis patients given menaquinone-7 showed large reductions in calcium deposits in the blood vessels, a major mortality risk factor in advanced kidney disease. Vitamin K deficiency, as assessed by high dp-ucMGP levels, is profound in hemodialysis patients from the Eastern Mediterranean region and it is significantly correlated with vascular calcifications. Daily 360 μg of menaquinone-7, given for 4 weeks, effectively reduces dp-ucMGP in this population.
CLEARING THE MYTHS OF SOY AND BREAST CANCER RISK AND SURVIVAL..
SOY FOOD INTAKE AND BREAST CANCER SURVIVAL. Published in reputable medical journal, JAMA. 2009;302(22):2437-2443. doi:10.1001/jama.2009.1783
The Shanghai Breast Cancer Survival Study, a large, population-based cohort study of 5042 female breast cancer survivors in China. Women aged 20 to 75 years with diagnoses between March 2002 and April 2006 were recruited and followed up through June 2009 revealed the truth and Clearing the myths of soy isoflavones and breast cancer risk and survival.
The soy constituents have been shown to have anticancer properties and improve cardiovascular and bone health, the estrogen-like effect of soy isoflavones and conflicting data from in vivo and in studies studies regarding the role of soy constituents in stimulating cell proliferation have raised a concern about The safety of soy food consumption among breast cancer survivors. Because concentrated soy isoflavones are increasingly being added to a wide variety of foods, including beverages, nutrition bars, yogurt, baked goods, meal replacements, and confections, exposure to isoflavones is becoming ubiquitous, Which is heightening concern about soy food consumption among the rapidly increasing population of breast cancer survivors.
During the median follow-up of 3.9 years (range, 0.5-6.2 years), 444 deaths and 534 recurrences or breast cancer–related deaths were documented in 5033 surgically treated breast cancer patients. Soy food intake, as measured by either soy protein or Soy isoflavone intake, was inversely associated with mortality and recurrence. The hazard ratio associated with the highest quartile of soy protein intake was 0.71 (95% confidence interval [CI], 0.54-0.92) for total mortality and 0.68 (95% CI, 0.54 -0.87) for recurrence compared with the lowest quartile of intake. The multivariate-adjusted 4-year mortality rates were 10.3% and 7.4%, and the 4-year recurrence rates were 11.2% and 8.0%, respectively, for women in the lowest And highest quartiles of soy protein intake. The inverse association was evident among women with either estrogen receptor–positive or –negative breast cancer and was present in both users and nonusers of tamoxifen.
To our knowledge, only 1 epidemiological study, the Life After Cancer Epidemiology (LACE) study, has evaluated the association of postdiagnosis soy isoflavone intake with cancer recurrence. An inverse association was suggested for postmenopausal women who had used tamoxifen.
In our comprehensive evaluation of soy food consumption and breast cancer outcomes using data from a large, population-based cohort study, we found that soy food intake was inversely associated with mortality and recurrence. The inverse association did not appear to vary by menopausal status and Was evident for women with ER-positive and ER-negative cancers and early and late-stage cancers.
Of the many constituents of soy food, soy isoflavones are the most intensively studied phytochemicals for their health-related effects. It has been shown that soy isoflavones compete with endogenous estrogens in the binding of estrogen receptors, increase the synthesis of sex hormone–binding globulin (Thus lowering the biological availability of sex hormones), inhibit 17β-hydroxysteroid dehydrogenases (thus reducing estrogen synthesis), and increase clearance of steroids from the circulation. These antiestrogenic effects may be one of the underlying mechanisms through which soy food consumption is associated with Better breast cancer outcomes.
Estrogen is believed to play a central role in breast cancer development and progression. Blocking the effect of estrogen, either by inhibiting estrogen action or by reducing estrogen production, has been widely used in breast cancer treatment as an adjuvant therapy. Soy foods are rich in Phytoestrogens, mainly in the form of isoflavones, which are natural estrogen receptor modulators that possess both estrogen-like and antiestrogenic properties. Soy constituents have also shown to have other anticancer effects, including the inhibition of DNA topoisomerase I and II, proteases, tyrosine Kinases, inositol phosphate, and angiogenesis and may also boost immune response and possessive antioxidative effects.
For more information, please visit: https://www.youtube.com/watch?v=LgPvW-RunKc
EnerFlex Breast Cancer Awareness Sharing Session: https://www.youtube.com/watch?v=MXqbFBo7KXA&feature=youtu.be
EnerFlex® PLUS 2.0 - Breast, Bone, Heart and Kidney Health with 180mcg MK-7/K2
- Brand: MYHEALTHDRIVER
- Product Code: EN-PLUS 2.0 [ 20g x 15 sachets]
- Availability: In Stock
- Ex Tax: $36.10